Patents by Inventor Neil Chaplin

Neil Chaplin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-specific T-cell engager specific for BCMA
    Patent number: 11492408
    Abstract: The present invention provides a bi-specific molecule which comprises: (i) a first domain which binds B cell maturation antigen (BCMA) and comprises at least part of a proliferation-inducing ligand (APRIL); and (ii) a second domain capable of activating a T cell. The invention also provides the use of such a molecule in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: November 8, 2022
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin
  • April variants
    Patent number: 10752665
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL) which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: August 25, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • Ligand
    Patent number: 10611811
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 7, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • Ligand
    Publication number: 20170334964
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 23, 2017
    Inventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
  • APRIL VARIANTS
    Publication number: 20160362467
    Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.
    Type: Application
    Filed: February 26, 2015
    Publication date: December 15, 2016
    Applicant: UCL Business PLC
    Inventors: Martin PULE, Kwee YONG, Lydia LEE, Neil CHAPLIN, Ben DRAPER
  • Molecule
    Publication number: 20160311915
    Abstract: The present invention provides a bi-specific molecule which comprises: (i) a first domain which binds B cell maturation antigen (BCMA) and comprises at least part of a proliferation-inducing ligand (APRIL); and (ii) a second domain capable of activating a T cell. The invention also provides the use of such a molecule in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
    Type: Application
    Filed: October 10, 2014
    Publication date: October 27, 2016
    Applicant: UCL BUSINESS PLC
    Inventors: Martin Pulé, Kwee Young, Lydia Lee, Neil Chaplin